Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (B.H.U.) Varanasi-221005 (U.P.), India.
Mini Rev Med Chem. 2019;19(19):1627-1642. doi: 10.2174/1389557519666190625165512.
One-third of the world's population harbours the latent tuberculosis infection (LTBI) with a lifetime risk of reactivation. Although, the treatment of LTBI relies significantly on the first-line therapy, identification of novel drug targets and therapies are the emerging focus for researchers across the globe. The current review provides an insight into the infection, diagnostic methods and epigrammatic explanations of potential molecular targets of dormant phase bacilli. This study also includes current preclinical and clinical aspects of tubercular infections and new approaches in antitubercular drug discovery.
世界上有三分之一的人口携带潜伏性结核感染（LTBI），一生中存在再激活的风险。尽管 LTBI 的治疗主要依赖于一线疗法，但寻找新的药物靶点和疗法是全球研究人员关注的新兴焦点。本综述提供了对潜伏阶段细菌的感染、诊断方法和潜在分子靶标的简要说明的深入了解。本研究还包括结核感染的当前临床前和临床方面以及抗结核药物发现的新方法。
